Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
about
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesSubcutaneous abatacept for the treatment of rheumatoid arthritis.New pharmacological strategies in rheumatic diseasesRefining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous TocilizumabTNF inhibitor therapy for rheumatoid arthritisLong-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsInvestigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles.Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trialsBiologic therapy for autoimmune diseases: an update.Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis.Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trialEffect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes.Life-Threatening Gastrointestinal Mucosal Necrosis during Methotrexate Treatment for Rheumatoid Arthritis.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.Intercellular cross-talk among bone cells: new factors and pathways.Abatacept in the treatment of lupus.Evolution of treatment for rheumatoid arthritis.Abatacept: a review of its use in the management of rheumatoid arthritis.Update on the use of abatacept for the treatment of rheumatoid arthritis.Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis.Is there still a role for abatacept in the treatment of lupus?Adverse reactions to biologic agents and their medical management.Evolving paradigm of treatment for autoimmune hepatitis.Abatacept: A Review in Rheumatoid Arthritis.Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis.Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.Negative pressure wound therapy and skin grafting for necrotizing fasciitis in a patient with rheumatoid arthritis treated with abatacept: A case report.Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy.[Janus kinase inhibitors].Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.
P2860
Q26991673-DC217904-4F9B-4CC2-88EB-6AC537346B0CQ27692117-74DE6168-B904-44A8-B4C7-DE0C7E2DC0C7Q28073763-A8E651F3-3BE2-4013-AB38-1D9BD1C91F36Q28080677-710F2B10-9F47-494E-8F4B-9C39DA9C7D4BQ28972424-F89E60F7-D212-489B-80A9-4085C4F08BA1Q30811550-C3149A97-ED2A-488F-AE61-75F7BEE1E2DBQ30863740-8DFFB8C7-D771-4C7E-B1EF-8E1BC7AB08C3Q33809045-B3178AEB-96FE-4ED1-A761-E829DC50BCBDQ33849223-38966357-13CC-4F2C-B81C-4E8F23C9AE66Q34172853-6DDF57DB-084B-4C35-8F49-6AB00B3A293FQ34364057-BE09A55B-D90E-4C4E-9746-0CA824B43DDEQ34655597-2DE084FD-480D-4A9F-AF20-14080E4CA0F0Q34656204-781924E9-9C99-4AB1-B216-E3C0DE805CC4Q34752154-82AB0981-C82D-4417-BCB1-25106A891A21Q36300479-5D8B7D64-E001-4B2C-93FA-072D5D76A644Q36623126-5D220EC8-F1B0-4CA0-AC79-785E81B871EEQ36625596-6211DBB2-42E2-4620-ACC5-FED7458B54E4Q36626213-854187E0-07BF-4671-8B56-17D3600DA6ECQ37012723-F494C988-36F9-4FAA-AE1F-D238822E5907Q37243204-76FA8F1D-BCFD-4982-8F98-430A75F60B68Q37350778-F8DE8508-C1BC-41EC-BF84-651FF46DE873Q37358271-A99C4631-894D-459C-A7F5-EBB045825169Q37391811-DAE09CBC-95B8-478D-8EE8-7A715A45E32DQ37600477-C0E9F6C9-942D-4922-9347-450AADBBC3B5Q37994636-0E097BCC-2822-431F-A8BD-EBE1AB6825E3Q38032598-54847730-8B0B-4AC4-939D-BA2122F863AFQ38065767-6A2DDBB4-3B77-49BB-A438-C76BC78F3E91Q38116472-4EC6B39A-A818-42AD-8FD5-051BB794AC36Q38125240-3A54868F-CA5B-4482-B856-90D0BC2EDCEDQ38210539-C6DB7B12-B63A-4F23-B38D-56220341350CQ38227479-E44B341C-35E2-4E15-A47C-B606E5F322D7Q38238948-7C3C18A5-4027-4512-B792-3A8F397D95C6Q38730872-629B2D59-9A4F-440C-AD17-407025860F54Q39368606-79505F15-86C3-4DD7-ABBA-A919B93BB47AQ40044046-B0876A41-E3A7-4C05-8935-C0C7E36A04B2Q40710011-50FA56C4-8D7F-4352-B475-50FCAC135DCEQ40957071-79BA3640-4143-430E-B805-70A6F67206DEQ42044232-47DE7D9F-0F5A-46D7-8479-E2E6B36543D6Q43963029-26C72F53-EFCB-49DE-A0CA-C57C9A1873E8Q47380976-B5C04DF0-49AC-4D7C-9AB6-145FC423CC80
P2860
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Long-term safety, efficacy and ...... ar results from the AIM trial.
@ast
Long-term safety, efficacy and ...... ar results from the AIM trial.
@en
Long-term safety, efficacy and ...... ar results from the AIM trial.
@en-gb
type
label
Long-term safety, efficacy and ...... ar results from the AIM trial.
@ast
Long-term safety, efficacy and ...... ar results from the AIM trial.
@en
Long-term safety, efficacy and ...... ar results from the AIM trial.
@en-gb
prefLabel
Long-term safety, efficacy and ...... ar results from the AIM trial.
@ast
Long-term safety, efficacy and ...... ar results from the AIM trial.
@en
Long-term safety, efficacy and ...... ar results from the AIM trial.
@en-gb
P2093
P2860
P356
P1476
Long-term safety, efficacy and ...... ar results from the AIM trial.
@en
P2093
Anthony S Russell
Carlos Abud-Mendoza
Charles Peterfy
Harry K Genant
Jacek Szechinski
Jean-Claude Becker
Joel M Kremer
Rene Westhovens
Richard Aranda
P2860
P304
P356
10.1136/ARD.2010.139345
P407
P50
P577
2011-10-01T00:00:00Z
P5875
P6179
1025298808